anlotinib – Medxy AI

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma

By MedXY 01/20/2026

This Phase II trial evaluates first-line anlotinib plus anthracyclines and ifosfamide followed by anlotinib maintenance for advanced soft-tissue sarcoma, showing an objective response rate of 30.8% and a manageable safety profile, suggesting a promising new treatment strategy.

news Oncology Respiratory

Triple-Combination Breakthrough: Penpulimab, Anlotinib, and Chemotherapy Set New Standards for Resectable NSCLC

By MedXY 01/19/2026

The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment paradigms.

Clinical Updates news Oncology

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY 09/19/2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.